Altimmune (ALT) Current Assets (2010 - 2026)

Altimmune (ALT) has 17 years of Current Assets data on file, last reported at $334.7 million in Q1 2026.

• On a quarterly basis, Current Assets rose 115.56% year-over-year to $334.7 million in Q1 2026; TTM through Mar 2026 was $334.7 million, a 115.56% increase from a year earlier, with the FY2025 full-year figure at $278.2 million, up 102.68% from the prior year.
• Current Assets for Q1 2026 stood at $334.7 million, up from $278.2 million in the prior quarter.
• Over the last five years, Current Assets for ALT reached as high as $334.7 million in Q1 2026 and fell as low as $137.3 million in Q4 2024.
• Historically, Current Assets has averaged $194.7 million across 5 years, with a median of $188.4 million in 2025.
• Across the five-year window, Current Assets slumped 34.52% in 2024 and surged 115.56% in 2026, its largest moves.
• Year by year, Current Assets stood at $192.8 million in 2022, then increased by 8.72% to $209.6 million in 2023, then slumped by 34.52% to $137.3 million in 2024, then soared by 102.68% to $278.2 million in 2025, then increased by 20.3% to $334.7 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $334.7 million in Q1 2026, $278.2 million in Q4 2025, and $216.6 million in Q3 2025.